Killion J W, Morrison D C
Infect Immun. 1986 Oct;54(1):1-8. doi: 10.1128/iai.54.1.1-8.1986.
C3H/HeJ mice were immunized intraperitoneally (i.p.) with lipopolysaccharide (LPS)-lipid A-associated protein (LAP) complexes or with purified protein-free LPS prior to lethal i.p. or intravenous Salmonella typhimurium LT2 challenge. Our results demonstrated that these Salmonella-hypersusceptible mice can be effectively protected against 1,000 100% lethal doses of S. typhimurium LT2 (i.e., 1,000 viable bacteria) administered by intravenous challenge when previously immunized with LAP-LPS complexes. In contrast to these results, immunization with LPS afforded markedly less protection regardless of the route of challenge, thus suggesting that the LAP portion of LAP-LPS complexes may be necessary for inducing protection against Salmonella infections. For most experiments, antigens were emulsified in complete Freund adjuvant (CFA); however, the CFA portion of the vaccine was suggested not to be an essential component for the induction of immunity to Salmonella infections, since equivalent levels of protection were obtained when it was omitted from the vaccine. The induction of immunity to murine salmonellosis by prior immunization with CFA-LAP-LPS was demonstrated not to be a transient phenomenon, since C3H/HeJ mice were still protected against lethal S. typhimurium LT2 challenge as late as 225 days postimmunization.
在经腹腔或静脉注射致死剂量的鼠伤寒沙门氏菌LT2攻击之前,给C3H/HeJ小鼠腹腔注射脂多糖(LPS)-脂质A相关蛋白(LAP)复合物或纯化的无蛋白LPS。我们的结果表明,这些对沙门氏菌高度敏感的小鼠,在预先用LAP-LPS复合物免疫后,可有效抵御静脉注射攻击的1000个100%致死剂量的鼠伤寒沙门氏菌LT2(即1000个活细菌)。与这些结果相反,无论攻击途径如何,用LPS免疫提供的保护明显较少,因此表明LAP-LPS复合物的LAP部分可能是诱导抵御沙门氏菌感染所必需的。对于大多数实验,抗原在完全弗氏佐剂(CFA)中乳化;然而,疫苗中的CFA部分被认为不是诱导对沙门氏菌感染免疫的必需成分,因为从疫苗中省略CFA时可获得同等水平的保护。预先用CFA-LAP-LPS免疫诱导对鼠沙门氏菌病的免疫不是一种短暂现象,因为在免疫后225天,C3H/HeJ小鼠仍能抵御致死性鼠伤寒沙门氏菌LT2的攻击。